Financial PerformanceLYRA reported EPS of $(0.18) versus consensus of $(0.22), showing better than expected financial performance.
Safety ProfileSupportive safety data from the 52-week ENLIGHTEN-1 safety extension study shows LYR-210 was generally well tolerated, consistent with the 24-week treatment, including repeat dosing.
Subgroup AnalysisSubgroup analysis with nasal polyps showed a positive effect versus sham in 3CS and nasal congestion scores, highlighting potential areas for successful treatment outcomes.